HK1255683A1 - Nalmefene for reduction of alcohol consumption in specific target populations - Google Patents

Nalmefene for reduction of alcohol consumption in specific target populations Download PDF

Info

Publication number
HK1255683A1
HK1255683A1 HK18114830.5A HK18114830A HK1255683A1 HK 1255683 A1 HK1255683 A1 HK 1255683A1 HK 18114830 A HK18114830 A HK 18114830A HK 1255683 A1 HK1255683 A1 HK 1255683A1
Authority
HK
Hong Kong
Prior art keywords
nalmefene
patient
alcohol
day
longer
Prior art date
Application number
HK18114830.5A
Other languages
English (en)
Chinese (zh)
Inventor
L‧托鲁普
L‧托魯普
A‧阿巴利基
A‧布拉德斯特拉姆
C‧佩尔松
D‧缪黎恩
P‧索伦森
T‧J‧延森
C‧佩爾松
J‧B‧奥斯特格尔德
D‧繆黎恩
P‧索倫森
J‧B‧奧斯特格爾德
Original Assignee
H‧隆德贝克有限公司
H‧隆德貝克有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48703496&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1255683(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H‧隆德贝克有限公司, H‧隆德貝克有限公司 filed Critical H‧隆德贝克有限公司
Publication of HK1255683A1 publication Critical patent/HK1255683A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Addiction (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
HK18114830.5A 2012-06-27 2018-11-20 Nalmefene for reduction of alcohol consumption in specific target populations HK1255683A1 (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201261664804P 2012-06-27 2012-06-27
US61/664,804 2012-06-27
US201261721539P 2012-11-02 2012-11-02
US61/721,539 2012-11-02
US201261736740P 2012-12-13 2012-12-13
US61/736,740 2012-12-13
US201361788810P 2013-03-15 2013-03-15
US61/788,810 2013-03-15

Publications (1)

Publication Number Publication Date
HK1255683A1 true HK1255683A1 (en) 2019-08-23

Family

ID=48703496

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18114830.5A HK1255683A1 (en) 2012-06-27 2018-11-20 Nalmefene for reduction of alcohol consumption in specific target populations

Country Status (35)

Country Link
US (4) US20140005217A1 (enExample)
EP (5) EP3345604B1 (enExample)
JP (3) JP6258933B2 (enExample)
KR (1) KR20150023396A (enExample)
CN (1) CN104411313A (enExample)
AU (1) AU2013283281B2 (enExample)
BR (1) BR112014032555A2 (enExample)
CA (1) CA2874703C (enExample)
CL (1) CL2014003484A1 (enExample)
CO (1) CO7160087A2 (enExample)
CY (3) CY1118579T1 (enExample)
DK (3) DK3138564T3 (enExample)
EA (1) EA029908B1 (enExample)
ES (4) ES2663532T3 (enExample)
FI (1) FI3345604T3 (enExample)
HK (1) HK1255683A1 (enExample)
HR (4) HRP20161717T1 (enExample)
HU (4) HUE031110T2 (enExample)
IL (1) IL236035B (enExample)
LT (3) LT3345604T (enExample)
ME (2) ME03030B (enExample)
MX (1) MX371373B (enExample)
MY (1) MY166914A (enExample)
NZ (1) NZ702191A (enExample)
PH (1) PH12014502798A1 (enExample)
PL (4) PL4223296T3 (enExample)
PT (3) PT3345604T (enExample)
RS (2) RS57046B1 (enExample)
RU (1) RU2665373C2 (enExample)
SG (1) SG11201408704WA (enExample)
SI (3) SI3138564T1 (enExample)
SM (3) SMT201800164T1 (enExample)
UA (1) UA114199C2 (enExample)
WO (1) WO2014001427A1 (enExample)
ZA (1) ZA201409525B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140005217A1 (en) 2012-06-27 2014-01-02 H. Lundbeck A/S Nalmefene for reduction of alcohol consumption in specific target populations
WO2014170353A1 (en) * 2013-04-17 2014-10-23 H. Lundbeck A/S Nalmefene for treatment of patients with sleep disorder
EP3134090B1 (en) 2014-04-22 2019-06-05 Otsuka Pharmaceutical Co., Ltd. Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders
US20170071590A1 (en) * 2015-09-10 2017-03-16 Suture Armor Llc Suture anchor
KR102699603B1 (ko) 2018-04-20 2024-08-29 삼성전자주식회사 반도체 메모리 소자

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3814768A (en) 1971-11-26 1974-06-04 Lewenstein E 6-methylene-6-desoxy dihydro morphine and codeine derivatives and pharmaceutically acceptable salts
US4535157A (en) 1983-11-01 1985-08-13 Key Pharmaceuticals, Inc. Process for making 6-desoxy-6-methylenenaloxone and 6-desoxy-6-methylenenaltrexone
US5086058A (en) * 1990-06-04 1992-02-04 Alko Ltd. Method for treating alcoholism with nalmefene
PL368612A1 (en) * 2001-08-14 2005-04-04 Biotie Therapies Corporation Method of treating alcoholism or alcohol abuse
UA102128C2 (en) 2008-12-05 2013-06-10 Х. Луннбек А/С Nalmefene hydrochloride dihydrate
MY158251A (en) 2009-05-25 2016-09-30 H Lundbeck As Method for the preparation of nalmefene hydrochloride
RS55777B1 (sr) 2010-11-05 2017-07-31 H Lundbeck As Postupak za proizvodnju naltreksona
JP5738470B2 (ja) 2011-03-31 2015-06-24 イムネクス ファーマ イラチュ サナイ ヴェ ティジャレット ア．シェ．Ｉｍｕｎｅｋｓ Ｆａｒｍａ Ｉｌａｃ Ｓａｎａｙｉ Ｖｅ Ｔｉｃａｒｅｔ Ａ．Ｓ． オピオイド拮抗体組成物、および強皮症の治療のためのその使用
US20140005217A1 (en) 2012-06-27 2014-01-02 H. Lundbeck A/S Nalmefene for reduction of alcohol consumption in specific target populations

Also Published As

Publication number Publication date
HRP20161717T1 (hr) 2017-02-10
WO2014001427A1 (en) 2014-01-03
EP3138564B1 (en) 2018-01-31
LT3345604T (lt) 2023-08-10
MX371373B (es) 2020-01-28
JP2018039810A (ja) 2018-03-15
KR20150023396A (ko) 2015-03-05
EP2866808A1 (en) 2015-05-06
ES2609122T3 (es) 2017-04-18
HUE031110T2 (en) 2017-06-28
EP3138564A1 (en) 2017-03-08
HRP20250329T1 (hr) 2025-05-09
HUE070621T2 (hu) 2025-06-28
SI3345604T1 (sl) 2023-08-31
JP2015521647A (ja) 2015-07-30
ES3014068T3 (en) 2025-04-16
SMT201800164T1 (it) 2018-07-17
UA114199C2 (uk) 2017-05-10
SMT201600471B (it) 2017-03-08
LT3138564T (lt) 2018-04-10
PH12014502798A1 (en) 2015-02-09
US20160375007A1 (en) 2016-12-29
HRP20230762T8 (hr) 2024-01-05
EP3345604B1 (en) 2023-06-07
SG11201408704WA (en) 2015-01-29
PT2866808T (pt) 2017-01-03
EA201492152A1 (ru) 2015-11-30
EP2866808B1 (en) 2016-11-02
ME03030B (me) 2018-10-20
RS55456B1 (sr) 2017-04-28
PL2866808T3 (pl) 2017-04-28
PL3138564T3 (pl) 2018-06-29
BR112014032555A2 (pt) 2017-06-27
ES2663532T3 (es) 2018-04-13
JP6258933B2 (ja) 2018-01-10
HK1208185A1 (en) 2016-02-26
CN104411313A (zh) 2015-03-11
LT2866808T (lt) 2017-01-10
CY1118579T1 (el) 2017-07-12
DK3138564T3 (en) 2018-03-26
EP4223296B1 (en) 2025-01-29
DK2866808T3 (en) 2017-01-16
CA2874703A1 (en) 2014-01-03
AU2013283281B2 (en) 2017-04-20
US20140005217A1 (en) 2014-01-02
RU2665373C2 (ru) 2018-08-29
SI2866808T1 (sl) 2017-01-31
PL3345604T3 (pl) 2023-08-28
PT3138564T (pt) 2018-04-03
DK3345604T3 (da) 2023-07-24
ZA201409525B (en) 2016-08-31
PT3345604T (pt) 2023-07-17
ME02587B (me) 2017-06-20
EP4223296C0 (en) 2025-01-29
FI3345604T3 (fi) 2023-07-28
ES2950492T3 (es) 2023-10-10
MX2014015488A (es) 2015-03-06
CY1126140T1 (el) 2023-11-15
EP4223296A2 (en) 2023-08-09
EP3345604A1 (en) 2018-07-11
EP4541421A2 (en) 2025-04-23
IL236035B (en) 2018-12-31
CL2014003484A1 (es) 2015-02-27
EA029908B1 (ru) 2018-05-31
PL4223296T3 (pl) 2025-04-14
US9642849B2 (en) 2017-05-09
US20140005216A1 (en) 2014-01-02
AU2013283281A1 (en) 2014-12-11
RS57046B1 (sr) 2018-05-31
CY1120097T1 (el) 2018-12-12
MY166914A (en) 2018-07-24
IL236035A0 (en) 2015-01-29
US10034874B2 (en) 2018-07-31
JP2019163275A (ja) 2019-09-26
EP4541421A3 (en) 2025-06-18
NZ702191A (en) 2017-06-30
US20180028526A1 (en) 2018-02-01
CO7160087A2 (es) 2015-01-15
HUE063313T2 (hu) 2024-01-28
JP6857684B2 (ja) 2021-04-14
CA2874703C (en) 2022-08-23
SI3138564T1 (en) 2018-04-30
EP4223296A3 (en) 2023-09-27
HRP20180363T1 (hr) 2018-04-20
RU2014151156A (ru) 2016-08-20
HRP20230762T1 (hr) 2023-10-13
HUE036272T2 (hu) 2018-06-28
SMT201600471T1 (it) 2017-03-08

Similar Documents

Publication Publication Date Title
JP6857684B2 (ja) 特定の標的集団におけるアルコール消費を低減するためのナルメフェン
JPWO2002078744A1 (ja) 精神神経疾患治療薬
HK1229720B (en) Nalmefene for reduction of alcohol consumption in specific target populations
HK1229720A1 (en) Nalmefene for reduction of alcohol consumption in specific target populations
HK1208185B (en) Nalmefene for reduction of alcohol consumption in specific target populations
CA2829280C (en) Compositions of opioid antagonists and their use for treating scleroderma
AU2022387440A1 (en) Methods and compositions for treating conditions associated with central hypoventilation
HK40112834A (zh) 用於痴呆和神经变性病况中的激越、精神病和认知衰退的环苯扎林治疗
WO2014170353A1 (en) Nalmefene for treatment of patients with sleep disorder
HK1219669A1 (en) Dosage form containing oxycodone and naloxone
HK1111604B (en) Dosage form containing oxycodone and naloxone